Spanish plasma products maker Grifols SA (GRF.MC) said Monday its purchase of Talecris Biotherapeutics Holdings Corp. (TLCR) for $3.4 billion will boost its earnings per share by 30% from the second year following completion of the transaction.

In a Spanish regulatory filing, Grifols said its annual sales will rise to $2.8 billion following the purchase, 58% of which will come from North America and 28% from Europe.

-By Jonathan House, Dow Jones Newswires; +34 91 395 8120; jonathan.house@dowjones.com
Grafico Azioni Grifols (PK) (USOTC:GIKLY)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Grifols (PK)
Grafico Azioni Grifols (PK) (USOTC:GIKLY)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Grifols (PK)